Meningococcal vaccine development: a novel approach

Bibliography

• RIEDO FX, PLIKAYTIS BD, BROOME CV: Epidemiology and prevention of meningococcal disease. Pediatr. In-fect. Dis. J. (1995) 14:643–657.
   PubMed Web of Science ®Google Scholar
• HART CA, ROGERS TR: Meningococcal disease. J. Med. Microbiol. (1993) 39:3–25.
   PubMed Web of Science ®Google Scholar
• JACKSON LA, WENGER JD: laboratory-based surveil-lance for meningococcal disease in selected areas, United States, 1989-1991. MMWR. (1993) 42:21–30.
   PubMedGoogle Scholar
• GOTSCHLICH EC, GOLDSCHNEIDER I, ARTENSTEIN MS: Human immunity to the meningococcus. IV. Irnmun o-genicity of group A and group C meningococcal poly-saccharides in human volunteers. J Exp. Med. (1969) 129:1367–1384.
   Google Scholar
• GOTSCHLICH EC, GOLDSCHNEIDER I, LEPOW ML, GOLD R: The immune responses to bacterial polysaccharides in man. In: Antibodies in Human Diagnosis and Therapy. Haber E, Krause RM (Eds.), Raven Press, New York, USA (1977):391–402.
   Google Scholar
• POOLMAN JT, BEUVERY EC, HOPMAN CTP et al.: Class 1/3 outer membrane protein vaccine against group B, type 15, subtype 16 meningococci. Dev. Biol. Stand. (1986) 63:147–152.
   PubMedGoogle Scholar
• ALA'ALDEEN DAA, STEVENSON P, GRIFFITHS E eta].: Im-mune responses in humans and animals to meningo-coccal transferrin-binding proteins: implications for vaccine design. Infect. Immun. (1994) 62:2984–2990.
   Google Scholar
• GOTSCHLICH EC: The meningococcal serogroup B vac-cine protection trials: concluding remarks at the re-por t meeting second day. NIPHAnn. (1991) 14:247–250.
   Google Scholar
• NORONHA CP, STRUCHINER CJ, HALLORAN ME: Assess-ment of the direct effectiveness of BC meningococcal vaccine in Rio de Janeiro, Brazil: a case-control study. Int. J. Epidemiol. (1995) 24:1050–1057.
   PubMed Web of Science ®Google Scholar
• BOSLEGO JW, GARCIA J, CRUZ C et al.: Efficacy, safety, and immunogenicity of a meningococcal group B (15:P1.3) outer membrane protein vaccine in Iquique, Chile. Chilean National Committee for Meningococcal Disease. Vaccine. (1995) 13:821–829.
   Google Scholar
• BJUNE G, CLOSS O, FROHOLM LO eta].: Design of clini-cal trials with an outer membrane vesicle vaccine against systemic serogroup B meningococcal disease in Norway. NIPH Ann. (1991) 14:81–91.
   Google Scholar
• GOLD R, LEPOW ML, GOLDSCHNEIDER I et al.: Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants./ C/in. Invest. (1975) 56:1536–1547.
   PubMed Web of Science ®Google Scholar
• GOLD R, LEPOW ML, GOLDSCHNEIDER I eta].: Immune response of human infants to polysaccharide vaccines of Groups A and C Neisseria meningitidis. J. Infect. Dis. (1977) 136S:S31–S35.
   Google Scholar
• GOLD RM, LEPOW ML, GOLDSCHNEIDER I et al.: Anti-body responses of human infants to three doses of group A Neisseria meningitidis vaccine administered at two, four and six months of age. J Infect. Dis. (1978) 138:731–735.
   PubMed Web of Science ®Google Scholar
• ANDERSON EL, BOWERS T, MINK CM eta].: Safety and im-munogenicity of meningococcal A and C polysaccha-ride conjugate vaccine in adults. Infect. Immun. (1994) 62:3391–3395.
   Google Scholar
• TVVUMASI PA, Jr., KUMAH S, LEACH A et al.: A trial of a group A plus group Cmeningococcal polysaccharide-protein conjugate vaccine in African infants. J Infect. Dis. (1995) 171 :632–638.
   Google Scholar
• FUSCO PC, MICHON F, TAI JY et al.: Preclinical evalua-tion of a novel group B meningococcal conjugate vac-cine that elicits bactericidal activity in both mice and non human primates. J. Infect. Dis. (1997) 175:364–372.
   PubMed Web of Science ®Google Scholar
• LEACH A, TVVUMASI PA, KUMAH S eta].: Induction of im-munologic memory in Gambian children by vaccina-tion in infancy with Group A plus Group C meningococcal polysaccharide-protein conjugate vac-cine. J. Infect. Dis. (1997) 175:200–204.
   Google Scholar
• GRANOFF DM, MCHUGH YE, RAFF HV eta].: MF59 adju-vant enhances antibody responses of infant baboons immunized with Haemophilus influenzae Type b and Neisseria meningitidis group c oligosaccharide-CRM197 conjugate vaccine. Infect. Immun. (1997) 65:1710–1715.
   Google Scholar
• BARTOLONI A, NORELLI F, CECCARINI C eta].: Irnmuno-genicity of meningococcal B polysaccharide conju-gated to tetanus toxoid or CRM197 via adipic acid dihydrazide. Vaccine. (1995) 13:463–470.
   Google Scholar
• DEVI SJ, ZOLLINGER WD, SNOY PJ et al.: Preclinical evaluation of group B Neisseria meningitidis and Escherichia coliK92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infect. Immun. (1997) 65:1045–1052.
   PubMed Web of Science ®Google Scholar
• ZOLLINGER WD, MORAN EE, DEVI SJ eta].: Bactericidal antibody responses of juvenile rhesus monkeys im-munized with group B Neisseria meningitidis capsu-lar polysaccharide-protein conjugate vaccines. Infect. Immun. (1997) 65:1053–1060.
   Google Scholar
• LIEBERMAN JM, CHIU SS, WONG VK eta].: Safety and im-munogenicity of a serogroups A/C Neisseria meningi-tidis oligosaccharide-protein conjugate vaccine in young children. A randomized controlled trial. JAMA (1996) 275:1499–1503.
   Google Scholar
• FAIRLEY CK, BEGG N, BORROW R eta].: Conjugate men-ingococcal serogroup A and C vaccine: reactogenicity and immunogenicity in United Kingdom infants. J. In-fect. Dis. (1996) 174:1360–1363.
   Google Scholar
• GOTSCHLICH EC, LIU T-Y, ARTENSTEIN MS: Human im-munity to the meningococcus. III. Preparation and im-munochemical properties of the group A, group B, and group C meningococcal polysaccharides. J Exp. Med. (1969) 129:1349–1366.
   Google Scholar
• KASPER DL, WINKELHAKE JL, ZOLLINGER WD eta].: lin-munochemical similarities between polysaccharide antigens of Escherichia cell° 7 : K1 (1) :NM and group B Neisseria meningitidis. J. Immunol. (1973) 110:262–268.
   Google Scholar
• WYLE SA, ARTENSTEIN MS, BRANDT BL eta].: Immuno-logic response of man to group B meningococcal poly-saccharide vaccines. J Infect. Dis. (1972) 126:514–522.
   Google Scholar
• ZOLLINGER WD, MANDRELL RE, GRIFFISS JM eta].: Com-plex of meningococcal group B polysaccharide and type 2 outer membrane protein immunogenic in man. Clin. Invest. (1979) 63:836–848.
   Google Scholar
• FINNE J, FINNE U, DEAGOSTINI-BAZIN H et al.: Occur-rence of a2-8 linked polysialosyl units in neural cell adhesion molecule. Biochem. Biophys. Res. Comm. (1983) 112:482–487.
   PubMed Web of Science ®Google Scholar
• FINNE J, LEINONEN M, MAKELA PRH: Antigenic similari-ties between brain components and bacteria causing meningitis. Lancet (1983) 2:355–357.
   PubMed Web of Science ®Google Scholar
• SAUKKONEN K, HALTIA M, FROSCH M eta].: Antibodiesto the capsular polysaccharide of Neisseria meningiti-dis group B or E. coli K1 bind to the brains of infant rats in vitro but not in vivo. Microb. Pathog. (1986) 1:101–105.
   Google Scholar
• GOLDSCHNEIDER I, GOTSCHLICH EC, ARTENSTEIN MS:Human immunity to the meningococcus. I. The role of humoral antibodies. J Exp. Med. (1969) 129:1307–1326.
   PubMed Web of Science ®Google Scholar
• RAFF HV, DEVEREUX D, SHUFORD W et al.: Human monoclonal antibody with protective activity for Escherichia coliK1 and Neisseria meningitidisGroup B infections. J. Infect. Dis. (1988) 157:118–126.
   PubMed Web of Science ®Google Scholar
• GLODE MP, SUTTON A, MOXON ER eta].: Pathogenesis of neonatal Escherichia coil meningitis: induction of bacteremia and meningitis in infant rats fed E. coliK1. Infect. Immun. (1977) 16:75–80.
   Google Scholar
• DEVI SJN, ROBBINS JB, SCHNEERSON R: Antibodies topoly [(2-8)-a-N-acetylneuraminic acid] and poly [(2-9)-a-N-acetylneuraminic acid] are elicited by immunization of mice with Escherichia coil K92 con-jugates: potential vaccines for groups B and C menin-gococci and E. coli K1. Proc. Natl. Acad. Sci. USA (1991) 88:7179–7179.
   Google Scholar
• KIM KS, CROSS AS, ZOLLINGER WD eta].: Prevention andtherapy of experimental Escherichia coil infection with monoclonal antibody. Infect. Immun. (1985) 50:734–737.
   Google Scholar
• DIAZ ROMERO J, OUTSCHOORN IM: Current status of meningococcal group B vaccine candidates: capsular or noncapsular? Clin. Microbiol. Rev. (1994) 7:559–575.
   Google Scholar
• JENNINGS HJ, ROY R, GAMIAN A: Induction of meningo-coccal group B polysaccharide-specific IgG antibodies in mice by using an N-propionylated B polysaccharide-tetanus toxoid conjugate vaccine. J. Immunol. (1986) 137:1708–1713.
   PubMed Web of Science ®Google Scholar
• PON RA, LUSSIER M, YANG QL et al.: N-propionylated group B meningococcal polysaccharide mimics a unique bactericidal capsular epitope in group B Neis-seria meningitidis. J. Exp. Med. (1997) 185:1929–1938.
   PubMed Web of Science ®Google Scholar
• JENNINGS HJ, GAMIAN A, ASHTON FE: N-propionylated group B meningococcal polysaccharide mimics epi-tope on group B Neisseria meningitidis J. Exp. Med. (1987) 165:1207–1211.
   PubMed Web of Science ®Google Scholar
• JENNINGS HJ, BRISSON J, KULAKOWSKA M, MICHON F: Polysialic acid vaccines against meningitis caused by Neisseria meningitidis and Escherichia coil K1. In: Polysialic Acid. Roth J, Rutishauser U, Troy FA (Eds.), Birkhauser Verlag, Basel, Switzerland (1993):25–38.
   Google Scholar
• QI HL, TAI JY, BLAKE MS: Expression of large amounts of Neisserial porin proteins in Escherichia coli and re-folding of the proteins into native trimers. Infect. Im-mun. (1994) 62:2432–2439.
   PubMed Web of Science ®Google Scholar
• WETZLER LM, HO Y: Neisserial porins induce upregula-tion of B cell costimulatory ligand, B7-2: possible mechanisms behind their adjuvant activity. In: Vac-cines '95. (Anonymous), Cold Spring Harbor Press, New York, USA (1995):237–242.
   Google Scholar
• WETZLER LM: Irnmunopotentiating ability of neisserial major outer membrane proteins. Use as an adjuvant for poorly immunogenic substances and potential use in vaccines. Ann. N Y Acad. Sci. (1994) 730:367–370.
   Google Scholar
• WETZLER LM, HO Y, REISER H: Neisserial porins induce B lymphocytes to express costimulatory B7-2 mole-cules and to proliferate. J Exp. Med. (1996) 183:1151–1159.
   PubMed Web of Science ®Google Scholar
• SNAPPER CM, ROSAS FR, KEHRY MR et al.: Neisserial porins may provide critical second signals to polysaccharide-activated murine B cells for induction of immunoglobulin secretion. Infect. Immun. (1997) 65:pp.
   Google Scholar
• MINETTI CASA, TAI JY, BLAKE MS eta].: Structural and functional characterization of a recombinant PorB class 2 protein from Neisseria meningitidis. Confor-mational stability and porin activity. J Biol. Chem. (1997) 272:10710–10720.
   Google Scholar
• SONG J, MINETTI CASA, BLAKE MS, COLOMBINI M: Suc-cessful recovery of the normal electrophysiological properties of PorB (Class 3) porin from Neisseria men-ingitidis after expression in Escherichia coli and re-naturation. Biochem. Biophys. Acta. (1997). (In Press.)
   Google Scholar
• MANDRELL RE, AZMI FH, GRANOFF DM: Complement-mediated bactericidal activity of human antibodies to poly a2-8 N-acetylneuraminic acid, the capsular poly-saccharide of Neisseria meningitidis serogroup B. J Infect. Dis. (1995) 172:1279–1289.
   PubMed Web of Science ®Google Scholar
• HAYRINEN J, JENNINGS HJ, RAFF HV eta].: Antibodies to polysialic acid and its N-propyl derivative: binding properties and interaction with human embryonal brain glycopep tides./ Infect. Dis. (1995)171:1481–1490.
   Google Scholar
• TAI JY, MICHON F, FUSCO PC, BLAKE MS: Preclinical evaluation of a combination vaccine against groups A, B, and C meningococci in both mice and nonhuman primates. In: Pathogenic Neisseria. Zollinger WD, Frasch CE, Deal CD (Eds.), Bethesda, MD, USA (1996):214–215.
   Google Scholar
• ESKOLA J, OLANDER RM, HOVI T eta].: Randomised trial of the effect of co-administration with acellular pertus-sis DTP vaccine on immunogenicity of Haemophilus influenzae Type b conjugate vaccine. Lancet (1996) 348:1688–1692.
   Google Scholar
• FARQUHAR JD, HANKINS WA, DE SANCTIS AN et al.: Clinical and serological evaluation of a meningococcal polysaccharide vaccine groups A, C and Y. Proc. Soc. Exp. Biol. Med. (1978) 157:79–82.
   Google Scholar